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Summary
The pharmacokinetics of propofol are relatively well described in the
pediatric population. Recent work has confirmed the validity of
allometric scaling for predicting propofol disposition across different
species and for describing pediatric ontogenesis. In the first year of
life, allometric models require adjustment to reflect ontogeny of
maturation. Pharmacodynamic data for propofol in children are
scarcer, because of practical difficulties in data collection and the
limitations of currently available depth of anesthesia monitors for
pediatric use. Hence, questions relating to the comparative sensitivity
of children to propofol, and differences in time to peak effect relative
to adults, remain unanswered. Keo half-lives have been determined for
pediatric kinetic models using time to peak effect techniques but are
not currently incorporated into commercially available target-con-
trolled infusion pumps.
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Pediatric pharmacokinetics
The pharmacokinetics of propofol are relatively well
described in children, having been investigated in
healthy children (1–5), children with biliary atresia
(3), small children suffering from burns (6), critically
ill ventilated (7,8) and nonventilated children (9) and
neonates (10,11). Propofol disposition is generally
best described by a 3-compartment mamillary
model, with a rapidly equilibrating central compart-
ment, a second larger peripheral compartment and a
third, very large peripheral compartment. Propofol
pharmacokinetics are altered in children, compared
to adults. Comparative analyses have demonstrated
that on a per kilogram body weight basis, children
demonstrate increased clearance and larger volumes
of distribution relative to adults. In particular, the
volume of the central compartment is much greater
than in adults (12). Consequently, children require
higher induction and maintenance doses than adults
to achieve the same propofol blood concentration.
The influence of the larger central compartment
volume in children can be explored using pharma-
cokinetic simulation. Figure 1 compares the concen-
tration versus time profile resulting from a 1-h
propofol infusion (4 mgÆkg)1Æh)1) administered to an
adult [Diprifusor kinetics (1,13)] or to a 20-kg child
[Kataria kinetics (5)]. The larger central compartment
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volume in children results in markedly reduced
propofol plasma concentrations, relative to the adult.
Disentangling covariate effects
The evaluation of drug disposition in heterogeneous
patients groups, such as those encountered in the
pediatric ICU, can be complicated by the presence of
confounding factors. How can one separate the
influences that critical illness may have on pharma-
cokinetics from the affects of body size and matu-
rity? Body size and age are usually well correlated in
pediatric populations. Allometric scaling is a useful
and well-supported (14) approach to disentangle
body size effects from other correlated covariables,
such as age, in pediatric populations. Allometric
scaling relates body mass to metabolic rate (and
hence to drug clearance) using Kleiber’s Law. In
1932, Kleiber (15) demonstrated that basal metabolic
rate was proportional to body mass raised to the
power 0.75 and that this relationship applied to
animals ranging in size from a mouse to a whale.
When deriving pharmacokinetic data from pediatric
populations, if weight is selected as a initial covar-
iate and the three-quarter power relationship
applied a priori (to clearance parameters; volume
parameters are scaled to the power of 1), this allows
the influence of secondary covariates, which may be
correlated to weight, e.g. age, to be examined (16).
Knibbe et al. (17) explored the application of
allometric scaling to propofol pharmacokinetic
parameters obtained from rats, children (aged from
1 to 5 years), and adults. This work demonstrated
the validity of the allometric approach for predicting
drug disposition across different species and for
describing within-species ontogenesis, Figure 2.
A recent publication by the same group has
focused on defining the human body weight range
for which allometric scaling can accurately be
applied to predict propofol clearance (18). Allomet-
ric scaling alone could accurately predict propofol
clearance in children older than 2 years. However,
adjustment of the model to reflect maturation was
required to predict clearance in children younger
than 24 months, a demonstration that simple allo-
metric scaling reveals, but does not account for, age-
related differences in pharmacokinetics.
Propofol in neonates
The work of Allegaert and colleagues in recent years
has done much to inform propofol disposition and
metabolism in term and preterm neonates. Allegaert
(11) described markedly reduced clearance in a
group of nine neonates (4–25 days postnatal age)
after bolus injection of propofol. After appropriate
allometric scaling to 70 kg to allow comparison, the
clearance value was approximately 32%, and the
volume of distribution at steady state was appro-
ximately 44% of the corresponding values previ-
ously reported in infants. Scaled propofol clearance
rates approach adult values within the first 3 months
to 1 year of life (6,19), mirroring ontogenic develop-
ment of hepatic enzyme systems (20).
For infants and older children, the inclusion of
body weight alone as a model covariate accounts for
much of the observed interindividual variability in
propofol pharmacokinetics (5,8,9,19). Allegaert has
demonstrated that for neonates, postmenstrual and
postnatal age as markers of maturity, rather than
body weight, were the most influential factors, with
the youngest babies having the smallest clearance
values. Anderson (21) further explored this finding,
combining Allegaert’s neonatal clearance data with
Figure 1
Simulation of the concentration vs time profile resulting from a 1-
h propofol infusion (4 mgÆkg)1Æh)1) administered to a 20-kg child,
using three different pharmacokinetic models. Diprifusor kinetics
(adult) (1,13), Kataria (pediatric) (5), and Rigby-Jones (pediatric,
postcardiac surgery) (8). The Diprifusor kinetics are linearly
weight-scaled, hence the predicted profile shown would apply to
any given body weight, adult or child.
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clearance values derived from older children (5,6)
and adults (13,22,23). A sigmoid Emax model was
then applied to describe the maturation profile,
Figure 3. In this analysis, the maturation half-time
was calculated as 44 weeks. Anderson highlights the
need for additional study of propofol disposition in
infants to fully characterize the maturation profile in
the first 2 years of life.
Pediatric critical care and propofol infusion
syndrome (PRIS)
PRIS was first described in the literature in 1992 (24).
Shortly after, the syndrome was defined by Bray (25)
as a sudden onset of treatment-resistant bradycardia
leading to asystole, combined with at least one of the
following symptoms: lipemic plasma, clinically
enlarged or fat infiltrated liver, metabolic acidosis
or rhabdomylosis. The syndrome was associated
with long-duration (more than 48 h), high-dose
(more than 4 mgÆkg)1Æh)1) propofol infusions in
children under 12 years old. In 2001, reports of the
same propofol-related syndrome occurring in adult
ICU patients (26) led to the UK Commission on
Human Medicines (then Commission on Safety of
Figure 2 5
Evidence for applicability of allometric scaling of propofol pharmacokinetic parameters. Plots show clearance (upper left), intercompart-
mental clearance (upper right), volume of the central compartment (lower left), and volume of the peripheral compartment (lower right) of
propofol vs body weight in rats (bolus injection), children (postcardiac surgery, 6-h infusion), and adults (post-CABG, 5-h infusion). Figure
from Knibbe et al. (17).
Figure 3 6
Propofol clearance rates, scaled to 70kg, derived from neonates,
children, and adults. The solid line describes the maturation
process as a sigmoid Emax function of postmenstrual age.
Allegaert (10) hypothesizes that the influence of postnatal age
(PNA) on clearance reflects ontogeny of glucuronidation activity
during the first week of postnatal life. Figure from Anderson (21).
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Medicines) to recommend that propofol infusion
rates for sedation did not exceed 4 mgÆkg)1Æh)1(27).
In the following year, the same committee
announced the contraindication of propofol for the
sedation of critically ill children (28).
Eight years later, what have we learned about
PRIS? We know that it is a real phenomenon, with
the consistency of clinical reports of the syndrome,
the dose-dependency, and the temporal association
with propofol administration cited as reasons to
strongly support a causal relationship (29). Plausible
mechanisms have been suggested supporting the
implication of the lipid component of currently
availably propofol formulations in the pathology of
the syndrome (30,31). Whether a lipid-free propofol
formulation, such as fospropofol, would decrease
the risk of PRIS, or avoid it entirely, is as yet
unknown. However, the potential for direct toxicity
related to propofol itself, rather than the vehicle,
would remain (32).
In recent years, use of propofol sedation in
critically ill children in the United Kingdom has
been extremely limited in line with current recom-
mendations (33). The knowledge base regarding the
disposition of propofol in the critical care population
is hence based on studies carried out prior to the
2002 contraindication. Reed et al. (7) were first to
study propofol disposition in a critically ill pediatric
population, ranging from neonates to children aged
15 years. They concluded that the pharmacokinetics
were not dissimilar to studies of healthy children but
described substantial inter-patient variability that
could not be attributed to age or other demographic
effects. Rigby-Jones et al. (8) described altered kinet-
ics in very small babies (because of increased
peripheral distribution volume) and reduced meta-
bolic clearance in children recovering from cardiac
surgery, both findings leading to prolonged propofol
elimination times, see Figure 2. Body weight was the
most influential model covariate and although a
broad age range was studied (1 week to 12 years),
no additional influence of age could be supported. In
a nonventilated, postneurosurgical, pediatric popu-
lation (9), propofol clearance values were reported to
be twice as high as those previously described in
pediatric intensive care unit (PICU) patients (8),
emphasizing the impact that mechanical ventilation
and cardiac bypass have on propofol elimination
during postoperative sedation.
Pediatric propofol target-controlled infusion
(TCI)
There are at least two pediatric pharmacokinetic
models for propofol available for use in commer-
cially available TCI pumps: the Paedfusor (34,35)
and the Kataria kinetic set (5). The Kataria model is
based on data from 53 healthy children, ranging in
age from three to 11 years. Mean postdose sampling
duration was 214 min (range 52–811). The Paedfusor
pharmacokinetic set was derived as a preliminary
model (presumably based on pediatric data only) by
Schuttler and Ihmsen (12) during their development
of a pharmacokinetic model based on pooled data
from both adults and children. In Schuttler’s anal-
ysis, pediatric data comprised 96 children aged from
2 to 11 years, including the patient population on
which Kataria’s model was based (5) and data from
two further pediatric studies (1,2).
The Paedfusor model was prospectively validated
in 29 children (1–15 years) undergoing cardiac sur-
gery or cardiac catheterization procedures (34). In
this small study, the Paedfusor model’s predictive
performance was well within acceptable limits for
clinical use. A formal prospective analysis of the
predictive performance of the Kataria model in
children has not been published to date. However,
a study by Rigouzzo and colleagues involved TCI
administration of propofol to children (aged 6–13
years) using the Kataria model. Blood samples for
propofol plasma assay were collected (36). It was
reported that measured concentrations of propofol
were consistently higher than those predicted by the
Kataria model and that the margin of error increased
with the increasing propofol concentration.
The original analyses leading to the derivation of
the Kataria and Paedfusor models were based on
pharmacokinetic data only. However, values for Ke0
and the blood–brain equilibration rate constant have
been retrospectively generated for both models
using the time to peak effect (tpeak) (37) technique
(38). Tpeak is a model-independent pharmacody-
namic parameter that can be used to calculate a Ke0
value for a given pharmacokinetic set, after admin-
istration of a submaximal dose. The Ke0 value
derived is one that accurately predicts tpeak (37).
Mun˜oz’s analysis revealed that the peak effect of
propofol in children (132 s) occurs far later than in
adults (80 s). The explanation offered for this finding
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is that, relative to adults (Schnider model), simula-
tions using the pediatric model demonstrate a much
slower initial decline in plasma propofol concentra-
tions, Figure 4. As the postbolus tpeak is the conse-
quence of both decreasing plasma concentration and
increasing effect site concentration, this is a plausible
mechanism.
The experimentally derived tpeak value of 132 s
extrapolated to a Ke0 value for the Kataria model of
0.41 min)1 and for the Paedfusor model, 0.91 min)1.
However, current commercially available TCI de-
vices incorporating the Kataria and Paedfusor mod-
els do not include Ke0, i.e. plasma is the target of the
infusion, rather than the effect site, thus depriving
pediatric populations from the superior control
offered by effect site targeting systems (39–41).
Pediatric pharmacodynamics (PD)
While the pharmacokinetics of propofol in the
pediatric population are reasonably well described,
there is a relative paucity of pharmacodynamic data
(9,38,42).
Limitations of pediatric PD studies
Undertaking pharmacodynamic studies can be very
difficult in children and particularly so in intensive
care medicine. In a ‘real life’ scenario, rather than a
controlled volunteer study in adults, it is often
difficult or impossible to obtain data describing a full
drug concentration versus effect profile. This is
required for adequately quantifying hysteresis and
hence the derivation of Ke0. Arterial blood, the gold-
standard matrix for sampling during PK–PD studies
of rapidly acting drug compounds, is highly unlikely
to be available for children outside of critical care.
The insertion of a peripheral arterial line in children
purely for research purposes is classified as high risk
and cannot be justified (43); further, arterial line
insertion is typically carried out after induction of
anesthesia, and the opportunity to populate the
rising phase of the hysteresis loop is lost. The use of
venous blood sampling during pediatric pharmaco-
dynamic studies of intravenous sedative-hypnotics
presents a limitation that can in part be overcome by
careful study design, such as the incorporation of
equilibration stages to accompanying changes in
infusion rate. This stabilizes arterial and venous
blood concentrations and minimizes arterio-venous
differences as far as possible.
The use of intermittent pharmacodynamic mark-
ers, such as sedation scores, can also make it more
difficult to capture rapidly changing drug effects.
However, for extended continuous infusion studies,
COMFORT scores (44) can provide useful informa-
tion and have been successfully utilized as pharma-
codynamic markers for the development of complex
but clinically informative models of propofol phar-
macodynamics (9). Other limitations of sedation
scoring as a pharmacodynamic marker are inter- and
intra-observer variance and the impact that stimu-
lation required as part of a scoring system may have
on the underlying depth of sedation.
Figure 47
The unit disposition function of plasma vs time profile simulation with the Schnider model (adults) (22) and both the Kataria and Paedfusor
models. A shallower decline in plasma concentration, and a larger variability related to patient age, is observed with the pediatric models.
Figure from Munoz et al. (38).
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Additionally, researchers are unlikely to be able to
study single-drug effects in children. Hence, there is
a need for pragmatism regarding the concomitant
administration of other drugs with sedating effects
when evaluating propofol pharmacodynamics, such
as maintaining opioids infusions at a constant rate,
so adjunct drug contribution to pharmacodynamic
effects are at least unchanging after a period of
equilibration (45). In another strategy to deal with
multiple drug effects, Jeleazcov et al. (46) assumed
additive interactions between propofol and co-
administered opioids to derive pharmacodynamic
parameter values for each drug based on their
combined sedative effect, when measured using
bispectral index (BIS). They studied 59 children aged
from 1 to 16 years undergoing general surgery. A
two-stage pharmacodynamic analysis revealed an
age-dependency of the Ke0 value for propofol, with
Ke0 decreasing with increasing age. Tpeak, however,
showed a trend of increasing with age. These
findings may reflect true age-dependent differences
in propofol pharmacodynamics. Cortinez et al. (42)
have suggested that children may be more sensitive
to propofol than adults, based on higher calculated
CE50 values in adults than in children (3–11 years),
resulting from a study examining auditory evoked
potentials (AEP) following a submaximal bolus
propofol dose. However, a second study by the
same group which determined propofol effect site
concentrations at BIS value = 50 in adults and in
children aged 3–11 did not demonstrate significant
differences in propofol requirements (47). In con-
trast, Rigouzzo et al. (36) suggested that children
may be less sensitive than adults to propofol. In their
study of 45 children (6–13 years) and 45 adults
anaesthetized with TCI propofol, children demon-
strated higher measured and predicted propofol
plasma concentrations at a BIS value of 50 than the
adult patients. Conflicting results from such studies
may be in part related to the choice of depth of
anesthesia monitor and differences in the pharma-
cokinetic models used to administer propofol
and ⁄ or predict effect site concentrations.
Recently, a second smaller study by Rigouzzo
et al. (48) attempted to identify the best model for
describing propofol PK–PD in prepubertal children.
Propofol was administered to prepubertal children
(n = 16, 6–12 years) by TCI using the Kataria model
(5) and to adults and postpubertal children (n = 13,
13–35 years) using the Schnider model (49). BIS was
used as an effect measure. The recorded BIS data
from the prepubertal group were then compared to
predicted propofol concentrations generated using
several pharmacokinetic models; the Kataria model
used to administer propofol but also the Marsh (1),
Schuttler (12) and Schnider models, to evaluate
which model best described the data. BIS data from
the postpubertal ⁄ adult cohort was compared to
predicted concentrations generated by the Schnider
model only. The analysis revealed that the prepu-
bertal BIS vs predicted propofol concentration was
best described by the adult Schnider model, so in a
second stage of the analysis, the two cohorts were
pooled so that the influence of puberty on propofol
pharmacodynamic parameter estimates could be
examined. The authors hypothesize that the lack of
early sampling in the studies that led to the deriva-
tion of the pediatric models tested may explain their
perceived weakness at describing the initial phase of
propofol distribution kinetics, and hence the effect
on BIS. Additionally, the Schnider model is unique
among those explored in Rigouzzo’s analysis in that
both age and lean body mass are included as
covariates, thus allowing a more precise tailoring
of individual predicted propofol concentrations.
Analysis of the pooled data from both cohorts using
the Schnider model revealed that pubertal status
was a significant pharmacodynamic model covariate
with both KeO and Ce50 varying between children
and adults. The typical value of Ce50 was around
20% higher in children than in adults. Tpeak was
subsequently derived and found to be significantly
shorter in children at 0.71 min [0.37–1.64] median
[range] vs 1.73 [1.4–2.68] min in adults. This is in
contrast to the findings by Munoz (38), which the
authors suggest may relate to differences in effect
measure (BIS vs AEP) and methodological differ-
ences, including the use of different pharmaco-
kinetic models. The shorter Tpeak in younger
children supports the findings of Jeleacov and
colleagues (46).
Propofol, BIS, and children
The technology of BIS monitoring is based on an
algorithm developed from adults, hence its useful-
ness as a measure of anesthetic depth in children,
and particularly in infants, has long been questioned
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(50). Subsequent studies evaluating the relationship
between the bispectral index and established seda-
tion measures such as the Observer’s Assessment of
Alertness ⁄ Sedation (OAA ⁄ S) and the University of
Michigan Sedation Scale (UMSS) have provided
evidence that BIS monitoring can be a useful
measure of intravenous sedation in children older
than 2 years (51,52). Currently, evidence to suggest
that any of the alternative depth of anesthesia
monitors is more or less suitable than BIS for use
in children is limited (53–55).
Prospective BIS monitoring of children (n = 12,
1–12 years) in PICU was performed to investigate
the incidence of over-sedation and periods of
potential awareness during neuromuscular blockade
(56). Children were sedated with either midazolam
or propofol infusions, with supplemental doses of
midazolam, fentanyl, or morphine provided if addi-
tional sedation was deemed necessary, based on
physiological parameters. The BIS monitor was
concealed from clinical staff. During the 476 h of
sedation studied, over-sedation (BIS < 50) occurred
35% of the time, and under-sedation (periods of
potential awareness, BIS > 71) comprised 8% of the
time. Over-sedation was more likely to occur in
patients sedated with propofol, than with midazo-
lam (P < 0.0001). There are several limitations to this
study, not least the small cohort and the assumption
that BIS is a ‘gold standard’ measure of sedation in
the patients studied. However, the study results
suggest the need for a larger prospective trial to
establish the benefit of BIS-titrated sedation in
pediatric patients during the use of neuromuscular
blocking agents.
Recently, Tirel et al. (57) used TCI propofol to
evaluate the relationship between age and BIS
values, in a group of children aged from 3 to
15 years. Target propofol plasma concentrations
were held at 6, 4, and 2 lgÆmL)1 during periods
without surgical stimulation to allow collection of
BIS and raw EEG. In this study, there was no
statistically significant difference in BIS values at 4
and 6 lgÆmL)1. BIS values at 2 lgÆmL)1 were signif-
icantly different to those achieved at the higher
target concentrations but were also correlated with
the age of the children (r2 = 0.66), with the highest
BIS values being recorded in the youngest children.
Tirel et al. suggest this may reflect a true pharmaco-
dynamic difference between younger and older
children or could be influenced by the underlying
pharmacokinetics. The Kataria model used for TCI
does not include age as a covariate after it was
demonstrated that its inclusion only marginally
improved the model.
Park et al. (58) investigated the relationship
between BIS values and predicted plasma propofol
concentrations in 30 children aged from 2 to 7 years
during emergence from anesthesia. The Marsh
model was used to administer TCI propofol (1). On
completion of surgery, the target propofol concen-
tration was reduced from 3 lgÆmL)1 in 0.2 lgÆmL)1-
steps and BIS values were recorded. The authors
concluded that BIS was correlated with predicted
propofol concentration during emergence from
anesthesia but that the correlation was weaker than
that observed with an adult population. Addition-
ally, there was substantial interindividual variability
in the recorded BIS values at each predicted con-
centration.
These studies suggest caution when using BIS to
titrate propofol infusions in children and demon-
strate a lack of sensitivity of the BIS system to
discriminate at deep sedation levels in children.
Conclusion
This review has sought to identify current gaps in
the knowledge base of propofol use in the pediatric
population, in particular, aspects relating to drug
disposition and pharmacodynamic effect. Updated
information on issues that impact on day-to-day
clinical practice such as injection pain and PRIS were
also considered.
There are comprehensive data describing propofol
disposition across the pediatric age range, as a result
of much needed research in the neonatal population
in recent years. In addition, based on demonstration
of the applicability and limitations of allometric
scaling, there is now better understanding of the
mechanisms and predictability of changes in prop-
ofol pharmacokinetics from birth to maturity.
Given the practical restrictions described, and the
continued lack of a gold-standard depth of anesthe-
sia monitor for children, it is not surprising that
much remains to be elucidated regarding the phar-
macodynamics of propofol in the pediatric popula-
tion. Indeed, the knowledge base relating to adult
propofol pharmacodynamics has its own limitations,
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with genuine disagreement about the most
appropriate values for time to peak effect and
t1 ⁄ 2keO (59,60).
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